Multiple myeloma (MM) is a systemic hematologic malignancy defined by the neoplastic proliferation of plasma cells within the bone marrow. A hallmark of its clinical course is the development of myeloma bone disease (MBD), a debilitating complication occurring in approximately 90% of patients. Driven by uncoupled bone remodeling, MBD leads to progressive osteolysis and skeletal fragility [1], directly impacting patient survival and quality of life. While bone marrow biopsy, serological markers, …